Oxeia Biopharma

Last day. We close tonight at midnight PT. Dr. Vishal Bansal, trauma surgeon and inventor of OXE103: "When someone has a concussion that won't heal, I have no approved pharmacologic treatment to offer." "We can get children back into school, people back at work, service members back to duty, athletes back in the game. We just need to get there." Today is your chance to be part of the first potential treatment for concussion. 👉 Invest before we close invest.oxeiabiopharma.com #Concussion #BrainHealth #TBI #startengine #Biotech #BrainInjury Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

1 day left. We close tomorrow. Here's the case: • 4,000 years, still no drug. The treatment hasn't changed since ancient Egypt: rest and wait. • 85% responder rate in Phase 2a vs. 33% on standard care, published in Neurotrauma Reports • An estimated $200M+ head start. Daiichi Sankyo ran this molecule through 9 studies and 300+ patients, and we hold the rights. • $9B+ in team exits, including Arena ($6.7B, Pfizer) and Kythera ($2.1B, Allergan) Help us get there, and be part of it. 👉 Invest before we close. invest.oxeiabiopharma.com #Concussion #BrainHealth #TBI #startengine #Biotech #BrainInjury Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

2 days left. Biopharma had its busiest M&A year in half a decade. Brain therapeutics led the way, for the first time. OXE103 showed an 85% responder rate in Phase 2a, against 33% on standard care alone. Phase 2b is how the advice finally changes. There is still no FDA-approved drug for concussion. Two days remain. → Invest: invest.oxeiabiopharma.com Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

"About 85 of us would recover normally. However, there is about 15% of us that have these lingering symptoms, and they're pretty severe. They can continue for months and months, and they're debilitating." Oxeia board member and former NFL quarterback Alex Smith on The HeadRush Podcast. That 15% is exactly who Oxeia's early research targeted. Phase 2a: 85% responder rate vs. 33% on standard care, published in Neurotrauma Reports. 3 days left. We close September 24. 👉 Invest before we close. invest.oxeiabiopharma.com #Concussion #BrainHealth #TBI #startengine #Biotech #BrainInjury Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

3 days left. Why invest now? Two things could look different by the time we raise again: an endpoint validation study underway at the University of Kansas Medical Center, and our planned Phase 2b trial, 160 to 180 patients, data expected mid-2028. Phase 2a: 85% responded on OXE103 vs. 33% on standard care. 3 days. Join us. → Invest: invest.oxeiabiopharma.com Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

4 days left. We've spent this campaign answering the questions investors ask us most. Here's one: Concussion has been around 4,000 years. Why has no one solved it? It doesn't show up on a CT or MRI, so scans come back clean and patients get sent home. There's also never been an agreed way to measure if someone's improving, so no one could design a trial to prove a drug works. That's the gap we're closing now. Got a question? Reply below, or read all five: invest.oxeiabiopharma.com Closes Sept 24. Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

Oxeia CEO Dr. Michael Wyand on The HeadRush Podcast: "I describe it as like draining a battery. Your brain just drains the battery." That energy collapse is what OXE103 was designed to address. Phase 2a: 85% responder rate vs. 33% on standard care. 5 days left. 🎧 youtube.com/watch?v=D0gLF1AV… → Invest: invest.oxeiabiopharma.com Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

5 days left. 700+ investors are in. Get a concussion today, there's still nothing your doctor can prescribe. Phase 2a: 85% responded on OXE103 vs. 33% on standard care. Phase 2b is next, and this round funds it. Closes Sept 24. → Join us: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

6 days left to become a shareholder in Oxeia. Founders with $9B in prior combined exits. $100M+ in licensed development data. Backing from NFL QB Alex Smith and cornerback Richard Sherman, who both know concussion first hand. Right now there are zero approved treatments. We're aiming to be the first. Closes Sept 24. → Own a piece before we close: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

"Concussion treatments could be coming sooner than most of us may realize." Alex Smith in the Kansas City Star, as a father watching his son take the field: "I scrambled, took a hit, and my vision blurred. I stayed in. I threw a touchdown. I was diagnosed with a concussion. I pushed to play longer than I should have because you do." "Sports are valuable, and brain health is priceless. Head injuries require seriousness, not silence." Zero FDA-approved drugs for concussion. OXE103 showed an 85% responder rate in Phase 2a vs. 33% on standard care, published in Neurotrauma Reports. Phase 2b is next, and this round funds it. Closes Sept 24. → Read Alex in the Kansas City Star kansascity.com/opinion/artic… → View the offering on StartEngine invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

7 days left. Up to 21 million concussions a year in the US. One to four million become persistent. Nothing approved to treat them. This round advances Phase 2b, the trial that builds the foundation for potential FDA approval. Closes Sept 24. → Fund Phase 2b: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

Live today at 11am PT: Michael Wyand, Dr. Vishal Bansal, and Alex Smith on what Phase 2a showed, what Phase 2b tests, and why the FDA cleared OXE103 to move ahead with no additional safety studies. Ask us anything before this round closes. → Join live: luma.com/5i47xcc8 → See the offering. Closes Sept 24: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

8 days left. Grateful to everyone who has joined us this round. A founding team with $9B in prior exits. $100M+ in licensed development data that put us an estimated 5-7 years ahead. Backing from NFL quarterback Alex Smith and cornerback Richard Sherman. 1.4 to 4.2 million people a year live with persistent concussion symptoms, and there is no FDA-approved drug for any of them. Closes Sept 24. → See the offering: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

Tomorrow, 11am PT: our CEO Michael Wyand, CSO Dr. Vishal Bansal, and board member Alex Smith go live on the science behind OXE103, the Phase 2b trial, and what comes next. There is still no FDA-approved drug for concussion. Bring your questions. → Register: luma.com/5i47xcc8 → See the offering. Closes Sept 24: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

9 days left. Grateful to everyone who has joined us this round. Still time to get in. Zero approved drugs for concussion. The advice is still rest and wait. We want to do better than "Wait and see." OXE103 showed an 85% responder rate in Phase 2a vs. 33% on standard care, published in Neurotrauma Reports. Phase 2b is next, and this round funds it. Closes Sept 24. → Join the round: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

Last day: our 10% bonus share window closes at 1:30 PM PT today. Eligible investments of $2,500 or more may qualify, terms apply. Still no FDA-approved drug for concussion. This round funds Phase 2b and closes September 24. → Bonus ends 1:30 PM PT today: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational. Bonus shares subject to terms and eligibility.

Final hours: our 10% bonus share window closes tomorrow, September 15, at 1:30 PM PT. Eligible investments of $2,500 or more may qualify. Last bonus before we close September 24. Still no FDA-approved drug for concussion. This round funds Phase 2b. → Get in before the bonus closes: invest.oxeiabiopharma.com/?u… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational. Bonus shares are subject to the terms on the campaign page.

Meet the team this Thursday. CEO Michael Wyand, CSO Dr. Vishal Bansal, and board member Alex Smith go live Sep 17, 11am PT: what Phase 2a showed and what Phase 2b tests. Zero FDA-approved drugs for concussion. OXE103: 85% responder rate in Phase 2a vs. 33% on standard care. 10% bonus shares close 1:30 PM PT Mon, Sep 15 (terms apply). → Register: luma.com/5i47xcc8 Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational. Bonus shares subject to terms and eligibility.

10% bonus shares are open through September 15. Eligible investments of $2,500+ may qualify (terms apply). It's the last bonus window before this campaign closes. What it funds: Phase 2b. OXE103 showed an 85% responder rate in Phase 2a vs. 33% on standard care, published in Neurotrauma Reports. Zero FDA-approved drugs for concussion. → startengine.com/offering/oxe… Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational. Bonus shares subject to terms and eligibility.